Skip to main content
Explore URMC

menu

A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia

Research Question:
Does the grug Glasdegib help people with acute myeloid leukemia?

Basic Study Information

Purpose:
Glasdegib is being studied in combination with azacitidine for the treatment of adult patients with previously untreated acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy (Non-intensive AML population). Glasdegib is being studied in combination with cytarabine and daunorubicin for the treatment of adult patients with previously untreated acute myeloid leukemia (Intensive AML population).

Location: University of Rochester Cancer Center Pharmacy

Study Contact Information

Study Coordinator: Pfizer CT.gov Call Center
Email: ClinicalTrials.gov_Inquiries@pfizer.com

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search